S. M. Collins

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

M. Caligiuri, C. Hofmeister, D. Benson, 2011, Blood.

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Don M. Benson, C. Hofmeister, H. Kwon, 2013, Cancer Immunology, Immunotherapy.

The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM).

H. Kwon, D. Benson, G. Starling, 2011, Journal of Clinical Oncology.